Tenax Therapeutics to Present at Biotech Showcase Investor Conference
January 04 2019 - 8:30AM
Business Wire
Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical
company focused on identifying and developing drugs that address
diseases with high unmet medical need, today announced that the
Company will participate in Biotech Showcase Investor Conference in
San Francisco, which takes place January 7-9, 2019. Anthony
DiTonno, Chief Executive Officer of Tenax, is scheduled to present
on Wednesday, January 9 at 9:30 a.m. Pacific Time.
Biotech Showcase™ is an investor conference devoted to providing
private and public biotechnology and life sciences companies with
an opportunity to present to, and meet with, investors and
pharmaceutical executives in one place during the course of one of
the industry's largest annual healthcare investor conferences.
Investors and biopharmaceutical executives from around the world
gather in San Francisco during this bellwether week which sets the
tone for the coming year.
Now in its eleventh year, this rapidly growing conference
features multiple tracks of presenting companies, plenary sessions,
workshops, networking, and an opportunity to schedule one-to-one
meetings.
In addition to biopharmaceutical and life science company
executives, Biotech Showcase delegates include investors in private
and public companies, sector analysts, bankers and industry
professionals.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying and developing drugs that address diseases
with high unmet medical need. The Company has a world-class
scientific team including recognized global experts in pulmonary
hypertension. The Company owns the North American rights to develop
and commercialize levosimendan and has initiated a Phase 2 clinical
trial for the use of levosimendan in the treatment of Pulmonary
Hypertension associated with Heart Failure and preserved Ejection
Fraction (PH-HFpEF). For more information, visit
www.tenaxthera.com.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired the North American
rights to develop and commercialize levosimendan from Phyxius
Pharma, Inc.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the Company that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
Company’s control that could lead to delays in the clinical study,
new product introductions and customer acceptance of these new
products; matters beyond the Company’s control that could impact
the Company’s continued compliance with Nasdaq listing
requirements; the impact of management changes on the Company’s
business and unanticipated charges, costs and expenditures not
currently contemplated that may occur as a result of management
changes; and other risks and uncertainties as described in the
Company’s filings with the Securities and Exchange Commission,
including in its annual report on Form 10-K filed on April 2, 2018,
as well as its other filings with the SEC. The Company disclaims
any intent or obligation to update these forward-looking statements
beyond the date of this release. Statements in this press release
regarding management’s future expectations, beliefs, goals, plans
or prospects constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190104005020/en/
ICRStephanie Carrington,
646-277-1282stephanie.carrington@icrinc.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2023 to Sep 2024